Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios Pro Rata

Dive into the world of dealmakers across VC, PE and M&A with Axios Pro Rata. Delivered daily to your inbox by Dan Primack and Kia Kokalitcheva.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Nashville news?

Get a daily digest of the most important stories affecting your hometown with the Axios Nashville newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Columbus news?

Get a daily digest of the most important stories affecting your hometown with the Axios Columbus newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Dallas news?

Get a daily digest of the most important stories affecting your hometown with the Axios Dallas newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Austin news?

Get a daily digest of the most important stories affecting your hometown with the Axios Austin newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Atlanta news?

Get a daily digest of the most important stories affecting your hometown with the Axios Atlanta newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Philadelphia news?

Get a daily digest of the most important stories affecting your hometown with the Axios Philadelphia newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Chicago news?

Get a daily digest of the most important stories affecting your hometown with the Axios Chicago newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios NW Arkansas

Stay up-to-date on the most important and interesting stories affecting NW Arkansas, authored by local reporters

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top DC news?

Get a daily digest of the most important stories affecting your hometown with the Axios DC newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Illustration: Allie Carl/Axios

Rival vaccine makers are trying to elbow into the massive COVID-19 market, arguing for federal funding and claiming advantages over the current choices in the U.S.

Why it matters: There's huge remaining demand around the world, and researchers say there should be more support — including money — from the Biden administration to fill it.

State of play: Pfizer, Moderna and Johnson & Johnson developed highly effective vaccines at record speed, and have produced more than enough doses to vaccinate every American.

Yes, but: The rest of the world isn't getting the doses it needs from the U.S., and it's in America's interests to get as much of the world vaccinated as quickly as possible because of new variants.

  • New competitors say they can help fill that gap, but not without the kind of intense investments that helped the Big 3 get there.

What they're saying: "I feel like we've gotten on the deck of the aircraft carrier and declared 'Mission Accomplished' and it's just not," said Corey Casper, CEO of the Seattle-based Infectious Disease Research Institute, a nonprofit biotech organization.

Details: IDRI has partnered with the company ImmunityBio on what it calls "next-generation" vaccine candidates.

  • Another new candidate, based on "old school" technology, was developed at the Texas Children's Center for Vaccine Development and spun out to a network for manufacturers in developing nations. They partnered with vaccine maker, Biological E in India and could get emergency approval there soon.
  • Both IDRI and Texas Children's researchers say they've got candidates that are more scalable than the mRNA vaccines from Pfizer and Moderna, and which don't require the same cold storage.
  • Casper said IDRI's technology, which is set to begin phase 1/2 clinical trials soon, could be even more durable against COVID and its future variants. And it could scale up to 1 billion doses within six months — and even faster with government assistance. But so far, they've gotten none, Casper said.
  • Peter Hotez, a vaccine researcher at the Baylor College of Medicine who helped develop the Texas COVID-19 vaccine candidate, shared his frustrations.
  • "[Our vaccine] checks every global health box there is," Hotez said. "It's trusted and it works. And yet, everyone's focused on the shiny new toys."

The concern has gotten the attention of at least some members of Congress.

  • "I'm worried that we're prioritizing vaccine technology that may not necessarily be feasible to bring this pandemic to a close globally," Sen. Lisa Murkowski, R-Alaska, said during a Senate committee hearing on Thursday.

The other side: A senior health official for the Biden administration told Axios that Operation Warp Speed, now known as the Countermeasures Acceleration Group, is still working with other vaccine developers.

  • "This administration is investing in a unique, whole of government approach to develop new COVID-19 treatments and to respond to the health needs of the public," an HHS spokesperson said in an emailed statement.
  • The FDA has issued guidelines to help developers navigate the process, and the NIH has announced $36 million in awards to academic institutions researching pan-coronavirus vaccines.
  • "This remains a critical priority as we work to get control of this pandemic and prepare for future needs related to this virus, and will continue to innovate and adapt to meet those needs," the official said.

But, but, but: Hotez and Casper said they've seen a lack of support and urgency from administration officials and believe more interest, and money, needs to return to projects that are closer to becoming a reality.

  • "We're getting contacted weekly now by ministers of health and ministers of science who now realize that vaccines aren't coming," Hotez said. "It's a wonderful feeling to be able to make a difference in the world. The bizarre thing is the lack of engagement from the U.S. government."

Go deeper

Omicron variant found in Philadelphia man

A technician handles tubes containing swab samples for COVID-19. Photo: Ahmad Salem/Getty Images

A Northwest Philadelphia resident has tested positive for the Omicron variant, the Philadelphia Department of Public Health announced Friday.

Driving the news: The confirmed case of the new coronavirus variant involves a man in his 30s, the department said.

Updated 2 hours ago - World

Myanmar's deposed leader Aung San Suu Kyi sentenced to 4 years in prison

An anti-coup protest in Yangon, Myanmar.Photo: Hkun Lat/Getty Images

A Myanmar court sentenced the country's ousted leader, Aung San Suu Kyi, on Monday to four years in prison on charges of "inciting public unrest" and breaking COVID-19 protocols, per the New York Times.

Why it matters: It's the first of several verdicts that could result in the 76-year-old Nobel laureate being imprisoned for the rest of her life. The 11 charges she faces have been widely criticised as politically motivated.

5 hours ago - World

Pope Francis denounces European governments' migrant response

Pope Francis adresses refugees at the Reception and Identification Centre (RIC) in Mytilene on the island of Lesbos on Sunday. Photo: Louisa Gouliamaki/Pool/AFP via Getty Images

Pope Francis criticized European countries' response to migrants and asylum seekers during his visit to a refugee camp on the Greek island of Lesbos Sunday.

Why it matters: The pope said "migration is a humanitarian crisis that concerns everyone," but little had changed in the global response to displaced peoples since his first visit to Lesbos five years ago, per a transcript of his remarks. "Human lives, real people, are at stake. ... let us stop this shipwreck of civilization!"